This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

AcutePreventiveSafetyDosingDosingDosingMOASavings & SupportSavings
& SupportSavings & SupportFormulary CoverageResourcesResourcesProvider & Patient EducationPrior Authorization
Prescribing InformationIndicationsPatient InformationPatient Site
Nurtec ODT Savings and SupportNurtec ODT Savings and SupportHelp patients access savingsPer Managed Markets Insight & Technology, LLC since 01/27/25. Formulary data are current as of May 2025. The information provided is not a guarantee of coverage or payment (partial or full), and is subject to change without notice. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Please confirm coverage with each patient’s plan. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.

With step edit removals, some major national commercial plans have made it even easier for patients who have 4–14 headache days per month to access Nurtec ODT for preventive treatment.1

Share this copay card information with your patients.
  • Eligible patients with commercial insurance may pay as little as $0 per month†
  • Patients can download and activate a card to get started today by visiting nurtec.com/savings
Email copay card info
Loading
Email copay card info
LoadingEligible commercially insured patients can, for one time only, access Nurtec ODT at no cost while benefits are being verified for one prescription fill, with a maximum of 16 tablets total. Insurance coverage must be approved by the payor for patients to continue receiving Nurtec ODT with no out-of-pocket cost. No membership fees. Only available for commercially insured patients. This is not health insurance. Maximum annual benefit of $7,000. The full terms and conditions can be accessed at nurtec.com/terms-and-conditions.With support from our Patient Access Coordinators, Pfizer Migraine Patient Access provides important access and coverage resources for providers and for patients prescribed a Pfizer migraine medication, including:
  • Live support by phone for patients and providers
  • Education on the insurance authorization process
  • Information about Pfizer migraine copay programs for eligible commercially insured patients
Reach out to a Pfizer Migraine Patient Access Coordinator. Call 1-866-222-4183, Monday-Friday between 8:00 AM – 8:00 PM ET
Visit Pfizer Migraine Patient Access
Loading Pfizer has partnered with CoverMyMeds to help with the PA process and get patients access to Nurtec ODT if prescribed

Sign up to create a CoverMyMeds account, or if you already have an account, submit your PA.

 Sign up Loading Submit PA Loading Pfizer has partnered with CoverMyMeds to help with the PA process and get patients access to Nurtec ODT if prescribed

Sign up to create a CoverMyMeds account, or if you already have an account, submit your PA.

 Sign up Loading Submit PA LoadingPrior AuthorizationAccurate and complete PA submissions may help avoid delayed decisions from the health plan Pfizer has partnered with CoverMyMeds to help with the PA process and get patients access to Nurtec ODT if prescribedSign up to create a CoverMyMeds account, or if you already have an account, submit your PA.Sign upLoadingSubmit PALoadingKey reminders
  • A patient's full migraine history should be included in the PA submission for Nurtec ODT
  • Use of inaccurate or inappropriate ICD-10-CM code(s) to describe the patient's migraine diagnosis is a common reason for coverage denials
  • If a health plan denies coverage for Nurtec ODT, the appeals process can be initiated to ask the plan to reconsider its decision
 Need help navigating the prior authorization process?We've got tools and resources for you.Explore resourcesLoadingICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; PA=prior authorization.How to prescribe Nurtec ODTPlease follow these simple steps below: EMR=electronic medical record; FDA=US Food and Drug Administration; NDC=National Drug Code.

Looking for local coverage information?

Access our formulary lookup tool for more information about getting Nurtec ODT in your area.

 Formulary coverage lookup tool LoadingHave samples of Nurtec ODT delivered to your office Get samples LoadingReference:Nurtec ODT. Package insert. Pfizer Inc. Have samples of Nurtec ODT delivered to your office Get samples LoadingAccess additional resources to help you and your patients View resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-NNT-USA-4379
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.
Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.